SS Innovations International, Inc. reported record quarterly revenue of $10.0 million in Q2 2025, a 121.8% increase from the same period last year. Gross profit tripled to $5.9 million, with 23 SSi Mantra surgical robotic system installations, up 130% from Q2 2024.

In the first half of 2025, revenue increased by 85.6% to $15.1 million, with a net loss of $5.9 million. SSi Mantra surgical robotic system installations totaled 38, up 100% from the first half of 2024.

As of June 30, 2025, SS Innovations had no long-term debt and $11.4 million in cash and cash equivalents. The SSi Mantra cumulative installed base totaled 105 systems in seven countries, with 4,657 cumulative surgeries.

CEO Dr. Sudhir Srivastava highlighted strong revenue growth driven by SSi Mantra 3 unit sales. The company plans to submit a 510(k) application for multiple indications to the FDA by September 2025, aiming for global expansion and CE marking certification by late 2025.

In Q2 2025, SS Innovations’ common stock was listed on Nasdaq, with the SSi Mantra system performing its first robotic cardiac surgery in the Western Hemisphere. Subsequent events included the world’s first robotic telesurgery for weight loss and intercontinental robotic cardiac telesurgery.

Financially, SS Innovations reported total assets of $69.98 million as of June 30, 2025, with total liabilities of $27.95 million. The company’s net loss for the six months ended June 30, 2025, was $5.94 million.

Cash flows for the six months ended June 30, 2025, showed a net cash used in operating activities of $9.56 million, while financing activities provided a net cash of $21.70 million. The company ended the period with $17.61 million in cash and cash equivalents.

Read more at GlobeNewswire: SS Innovations Reports Second Quarter 2025 Financial